Benitec Biopharma Inc. cash flow statement BNTC

Annual Quarterly

In fiscal 2026, which ended Jun 30, 2026, Benitec Biopharma Inc. used $16.5 million of cash from operations, up 30.0% from the year before. It spent $105,000 on capital expenditures. Free cash flow was negative, at -$16.6 million.

USD in millions, except per-share amounts and ratios. The percent under a figure is the change from the year before.

Line	FY 2026 Jun 30, 2026	FY 2025 Jun 30, 2025	FY 2024 Jun 30, 2024	FY 2023 Jun 30, 2023	FY 2022 Jun 30, 2022	FY 2021 Jun 30, 2021	FY 2020 Jun 30, 2020
Operating
Depreciation and amortization	0 -12.1%	0 -24.1%	0 -36.0%	0 -18.6%	0 -27.7%	0 +21.6%	0
Stock-based compensation	26 +51.6%	17 +1999.5%	1 +83.6%	0 -48.0%	1 +37.2%	1 +167.5%	0
Operating cash flow	-17 +30.0%	-24 -21.6%	-19 -7.7%	-18 -13.3%	-16 -23.9%	-13 -70.3%	-8
Investing
Capital expenditures	0 +483.3%	0 -89.9%	0 +17800.0%	0 -92.3%	0 -94.1%	0 +132.6%	0
Investing cash flow	-0 -483.3%	-0 +89.9%	-0 -17800.0%	-0 +92.3%	-0 +94.1%	-0 -135.1%	-0
Financing
Financing cash flow	99 +40.4%	70 +3.6%	68 +324.8%	16 -28.9%	—	23 +1172.4%	2
Change in cash
Effect of exchange rate	—	—	—	—	—	0 +960.3%	-0
Net change in cash	82 +75.2%	47 -3.1%	48 +3154.2%	-2 +89.9%	-16	—	—
Free cash flow	-17 +29.6%	-24 -20.5%	-20 -8.7%	-18 -13.2%	-16 -21.9%	-13 -71.1%	-8
Per share
Free cash flow per share	-0.36 +45.2%	-0.65 +38.9%	-1.07 +91.8%	-13.00 +60.7%	-33.10	—	—
Ratios
Free cash flow margin	—	—	—	-24,017.33%	-21,797.26%	-22,123.73%	-7,865.98%
Capital expenditures to revenue	—	—	—	1.33%	17.81%	374.58%	97.94%
Stock-based compensation to revenue	—	—	—	602.67%	1,191.78%	1,074.58%	244.33%

How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and ratios. Capital expenditures, debt repaid, dividends, and buybacks are positive amounts. Investing and financing cash flow keep the filing sign, so an outflow is negative. Free cash flow is operating cash flow minus capital expenditures. Returned to shareholders is dividends plus buybacks. Free cash flow margin, capital expenditures, and stock-based compensation are divided by revenue. Cash conversion is operating cash flow divided by net income. More on our methodology.

Company profile

Industry: Pharmaceutical Preparations (SIC 2834)
Listed as: BNTC (Nasdaq)
Fiscal year ends: June 30
Incorporated in: DE
Headquarters: Hayward, CA
SEC filer status: Non-accelerated filer, Smaller reporting company
SEC CIK: 1808898

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.